Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy
Shots:
- Spark to get exclusive- WW license to develop- manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program
- The companies will work together and will leverage their knowledge to address unmet needs for people living with drug-resistant focal epilepsy
- CG01 is an investigational gene therapy that aims to treat drug resistant focal epilepsy
| Ref: Spark Therapeutics | Image: Ophthamology Innovation Summit
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
